Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

An oral formulation of iclaprim has successfully completed three Phase I trials: a radiolabelled ADME study (absorption, distribution, metabolism and excretion), a Phase I bioavailability trial with a solution and one with a capsule formulation. Arpida believes that the availability of an oral formulation could potentially fulfil an important clinical medical need for the treatment of serious bacterial infections, particularly those caused by MRSA. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge and outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's third most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against 611 pneumococcal clinical isolates from Europe, the USA and Asia irrespective of the mechanisms of resistance to currently used drugs. Arpida received authorisation to enter first-in-man studies with AR-709 in the UK in the second half of 2006.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating MRSA in preclinical models of skin infection and nasal carriage.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Inc. (Nasdaq: BMRN ) today announced that Joshua ... will present a company update at the Deutsche Bank 2010 ... 9:00 a.m. ET.   Interested parties may access ... investor section of the BioMarin website, www.BMRN.com .  A ...
... Dec. 6, 2010 SI-BONE, Inc. (San Jose, California), a ... minimally invasive surgical (MIS) device to treat the sacroiliac (SI) ... Institute, has joined its Medical Advisory Board (MAB). Dr. Rashbaum ... and Nick Shamie, along with SI-BONE founder, Mark Reiley, on ...
Cached Medicine Technology:BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 3SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 4
(Date:7/11/2014)... 11, 2014 Microbiology testing is a ... diagnostics industry, which is expected to pose the biggest ... sector owes its growth to the ongoing spread of ... worldwide and a major factor leading to the upsurge ... bio-terrorism, and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... , RICHMOND, Calif., Aug. 18 Transcept ... to reduce operating expenses by eliminating certain staff positions following ... Products to commercialize Intermezzo ((R) )(zolpidem tartrate sublingual tablet) ... Glenn A. Oclassen, President and Chief Executive Officer commented, ...
... SAN DIEGO, Aug. 18 Aethlon Medical, ... present at today,s 14th Annual Southern California Investor Conference ... California. The conference is hosted by California Equity Research ... world-recognized life science, technology, media, and real estate/financial organizations. ...
... ... today announced that the hemostatic HemCon Patch™ and HemCon® Bandage ... with Premier Purchasing Partners L.P., the group purchasing unit of Premier ... 2011. The agreement makes HemCon dressings available at pre-negotiated terms to ...
... , INDIANAPOLIS, Aug. 18 "If commercial flying ... fire, there would be a public revolt," said Rob Schnepp, CPTC ... Fire Department in California. "The numbers aren,t going down, and this ... NFPA study reveals 87-percent of people who died in fires had ...
... ... States Health Alliance Admitted to Talent Management Organization , ... Atkins, VA (PRWEB) August 18, 2009 -- The ... world-class companies, has two new members, Qwest, headquartered in Denver, Colorado, and Mountain States ...
... , ... Group (ISG), a nationwide network of identification and card issuance sales and service experts, ... the Medical Group Management Association (MGMA). , ... Kansas City, MO (PRWEB) August 18, 2009 -- Identification Systems ...
Cached Medicine News:Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 2Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 3Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 4Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 5Health News:Aethlon Medical to Present at Today's Southern California Investor Conference 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 3Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 2Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 2Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 4Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 2Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 3
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... the typical patient, right for the not-so-typical ... you have the ability to address the ... least expect themeven after implant. St. Jude ... to be prepared in almost any situation, ...
... Right for the typical patient, right ... Medical ICDs, you have the ability to ... when you least expect themeven after implant. ... you need to be prepared in almost ...
... Based Nursery ID and Visitor Control System. A ... hospital to compare and verify identity of those ... It helps document interactions with all visitors and ... a given child patient. It also helps to ...
Medicine Products: